SOPH logo

SOPHiA GENETICS SA Stock Price

NasdaqGS:SOPH Community·US$282.5m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

SOPH Share Price Performance

US$4.18
0.79 (23.49%)
53.6% undervalued intrinsic discount
US$9.00
Fair Value
US$4.18
0.79 (23.49%)
53.6% undervalued intrinsic discount
US$9.00
Fair Value
Price US$4.18
AnalystHighTarget US$9.00
AnalystConsensusTarget US$7.00
AnalystLowTarget US$6.00

SOPH Community Narratives

AnalystHighTarget·
Fair Value US$9 53.6% undervalued intrinsic discount

AI Adoption And Global Precision Medicine Will Expand Markets

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value US$7 40.3% undervalued intrinsic discount

Precision Medicine Advances Will Transform Global Healthcare Analytics

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·
Fair Value US$6 30.3% undervalued intrinsic discount

Revenue Lags And Margin Pressure Will Improve Eventually

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent SOPH News & Updates

Market Participants Recognise SOPHiA GENETICS SA's (NASDAQ:SOPH) Revenues Pushing Shares 28% Higher

Sep 30
Market Participants Recognise SOPHiA GENETICS SA's (NASDAQ:SOPH) Revenues Pushing Shares 28% Higher

Sophia Genetics Growth Story Clouded By Persistent Losses: Why I'm Choosing To Hold

Aug 26

Analysts Are Updating Their SOPHiA GENETICS SA (NASDAQ:SOPH) Estimates After Its Second-Quarter Results

Aug 08
Analysts Are Updating Their SOPHiA GENETICS SA (NASDAQ:SOPH) Estimates After Its Second-Quarter Results

Revenues Tell The Story For SOPHiA GENETICS SA (NASDAQ:SOPH) As Its Stock Soars 29%

Jul 10
Revenues Tell The Story For SOPHiA GENETICS SA (NASDAQ:SOPH) As Its Stock Soars 29%

SOPHiA GENETICS SA Key Details

US$69.7m

Revenue

US$22.5m

Cost of Revenue

US$47.2m

Gross Profit

US$120.6m

Other Expenses

-US$73.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-1.09
Gross Margin
67.78%
Net Profit Margin
-105.32%
Debt/Equity Ratio
61.9%

SOPHiA GENETICS SA Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet with very low risk.

2 Risks
1 Reward

About SOPH

Founded
2011
Employees
423
CEO
Jurgi Camblong
WebsiteView website
www.sophiagenetics.com

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Swiss Market Performance

  • 7 Days: 0.02%
  • 3 Months: 3.1%
  • 1 Year: 2.0%
  • Year to Date: 5.9%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Similarly, the market is flat for the past 12 months. Looking forward, earnings are forecast to grow by 11% annually. Market details ›